![]() |
市場調查報告書
商品編碼
2026801
結構生物學和分子建模市場預測至2034年—按產品、工具、技術、應用和區域分類的全球分析Structural Biology & Molecular Modeling Market Forecasts to 2034 - Global Analysis By Product, Tools (Software as a Service & Standalone Modeling, Visualization & Analysis, Databases and Other Tools), Technology, Application and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球結構生物學和分子建模市場規模將達到 80 億美元,並在預測期內以 18.2% 的複合年成長率成長,到 2034 年將達到 308 億美元。
結構生物學和分子建模是兩個密切相關的領域,在理解生物大分子分子結構和功能方面發揮著至關重要的作用。它們是用途廣泛的工具,從基礎研究到醫學、農業和工業等實際應用,應用範圍十分廣泛。它們使我們能夠從分子層面理解生物過程,並推動各個科學技術領域的進步。
根據 2021 年 9 月 MDPI日誌上發表的一篇研究論文,周邊動脈疾病(PAD) 的盛行率估計在 3% 到 12% 之間,影響著美國和歐洲約 2700 萬人。
慢性病增多
慢性疾病通常涉及複雜的分子路徑。結構生物學提供詳細信息,有助於識別和檢驗潛在的藥物靶點。結構生物學和分子建模有助於識別潛在的藥物標靶並設計特異性療法。癌症和神經退化性疾病等慢性疾病的日益普遍,推動了對標靶和個人化療法的需求。
我們對生物系統的理解有其局限性
儘管取得了進展,但我們對複雜生物系統的理解仍然不足。對目標蛋白3D結構的認知不足會阻礙有效候選藥物的識別和設計,可能導致藥物研發過程的延誤和效率降低。此外,蛋白質-配體相互作用的低可預測性以及生物系統的複雜性等因素也阻礙了市場成長。
人工智慧(AI)的整合
將人工智慧 (AI) 和機器學習 (ML) 應用於結構生物學和分子建模流程,可提高資料分析的速度和準確性。 AI 演算法能夠分析生物數據並識別潛在的藥物標靶。這有助於開發更有效率的藥物發現流程,從而提高治療效果並圖副作用。這種整合進一步提升了該領域藥物發現和開發活動的效率、準確性和整體成功率。
初始成本高
結構生物學和分子建模技術通常需要昂貴的設備、軟體和熟練的專業人員。這些技術高度依賴尖端技術和專用設備。此外,建立和維護一流的實驗室和專業設施需要大量的資金投入。另外,分析實驗數據的相關成本,例如軟體授權費和專業人員費用,也會增加初始成本,進而抑制市場需求。
新型冠狀病毒(COVID-19)的影響
生命科學領域的大量研究活動已轉向與新冠病毒相關的研究,包括疫苗研發、藥物再利用以及病毒結構和功能的解析。這種資源重新分配影響了非新冠病毒相關的研究領域,例如結構生物學和分子建模。疫情期間的經濟不確定性和優先事項的轉變給研究計畫的資金籌措帶來了挑戰。此外,尋找新冠病毒治療方法的迫切性也提高了人們對抗病毒藥物研發的興趣和投資,間接地惠及了結構生物學和分子建模領域。
在預測期內,電子顯微鏡領域預計將成為最大的細分市場。
電子顯微鏡領域預計將迎來強勁成長。電子顯微鏡擁有高解析度,使研究人員能夠觀察分子乃至原子層級的結構。它是結構生物學和分子建模領域的強大工具,能夠提供詳細的結構訊息,這對於理解生物過程和疾病機制以及加速藥物研發至關重要。電子顯微鏡技術的不斷進步進一步提升了其在該領域的重要性。
預計在預測期內,藥物研發領域將呈現最高的複合年成長率。
預計在預測期內,藥物研發領域將呈現最高的複合年成長率。結構生物學和分子建模在藥物研發中發揮著至關重要的作用,它們能夠提供關於疾病分子機制的寶貴見解,並有助於設計新型療法。這些技術有助於簡化藥物研發流程,使其更有效率且經濟。
由於研發投入的增加和技術的進步,預計亞太地區在預測期內將佔據最大的市場佔有率。亞太地區的製藥和生物技術產業有望顯著推動對結構生物學和分子建模工具的需求。此外,政府對科學研究和生物技術的扶持政策和資金投入也可能對市場產生正面影響。
由於持續的進步、合作與夥伴關係,預計歐洲在預測期內將呈現最高的複合年成長率。政府資助、私人投資和津貼在推動該地區結構生物學和分子建模研究方面發揮著至關重要的作用。歐洲市場的主要參與者包括達梭系統、Agile Molecules 和 Acerella Limited。此外,資金籌措機會和人們對個人化醫療日益成長的興趣也可能影響歐洲市場的成長。
According to Stratistics MRC, the Global Structural Biology & Molecular Modeling Market is accounted for $8.0 billion in 2026 and is expected to reach $30.8 billion by 2034 growing at a CAGR of 18.2% during the forecast period. Structural Biology and Molecular Modeling are two closely related fields that play a crucial role in understanding the structure and function of biological macromolecules at the molecular level. They are versatile tools with applications ranging from basic research to practical applications in medicine, agriculture, and industry. They provide a molecular-level understanding of biological processes, facilitating advancements in various scientific and technological fields.
According to the MDPI Journal research article published in September 2021, the prevalence of Peripheral Arterial Disease (PAD) is estimated to be 3-12%, affecting nearly 27 million people in America and Europe.
Rising incidence of chronic diseases
Chronic diseases often involve complex molecular pathways. Structural biology helps identify and validate potential drug targets by providing detailed information. Structural biology and molecular modeling contribute to the identification of potential drug targets and the design of specific therapeutics. The increasing prevalence of chronic diseases, such as cancer and neurodegenerative disorders, has fuelled the demand for targeted and personalized therapies.
Limited understanding of biological systems
Despite advancements, understanding of complex biological systems is still evolving. A limited understanding of the three-dimensional structures of target proteins can impede the identification and design of effective drug candidates. This can result in a slower and less efficient drug development process. Additionally, factors such as inaccuracy in predicting protein-ligand interactions and complexities of biological systems hampers the market growth.
Integration of artificial intelligence (AI)
The integration of artificial intelligence (AI) and machine learning (ML) in structural biology and molecular modeling processes enhances the speed and accuracy of data analysis. AI algorithms can analyze biological data to identify potential drug targets. It presents opportunities for the development of more efficient drug discovery pipelines, improving treatment efficacy and minimizing side effects. This integration further enhances the efficiency, accuracy, and overall success rate of drug discovery and development efforts in this field.
High initial costs
Structural biology and molecular modeling techniques often involve expensive equipment, software, and skilled personnel. They heavily rely on cutting-edge technologies and specialized equipment. Also, establishing & maintaining state-of-the-art laboratories and specialized facilities requires significant capital investment. Additionally, the costs associated with analyzing experimental data, including software licenses and skilled personnel for interpretation contribute to the overall initial expenses thereby hampering the market demand.
Covid-19 Impact
Many research efforts in the life sciences were redirected toward covid related studies, including vaccine development, drug repurposing, and understanding the virus's structure and function. This redirection of resources has impacted non-covid-related research areas, including structural biology and molecular modeling. Economic uncertainties and shifting priorities during the pandemic have led to funding challenges for research projects. Further, the urgency of finding treatments for covid has spurred increased interest and investment in antiviral drug discovery, which indirectly benefitted the structural biology and molecular modeling sector.
The electron microscopy segment is expected to be the largest during the forecast period
The electron microscopy segment is estimated to have a lucrative growth. Electron microscopy technique offers high resolution and allows researchers to visualize structures at the molecular and even atomic levels. It is a powerful tool in structural biology and molecular modeling, providing detailed structural information that is crucial for understanding biological processes, disease mechanisms, and facilitating drug discovery efforts. The continuous advancements in EM technology further contribute to its significance in the field.
The drug discovery segment is expected to have the highest CAGR during the forecast period
The drug discovery segment is anticipated to witness the highest CAGR growth during the forecast period. Structural biology and molecular modeling play crucial roles in drug discovery by providing valuable insights into the molecular mechanisms of diseases and facilitating the design of novel therapeutic agents. These techniques help streamline the drug discovery pipeline, making it more efficient and cost-effective.
Asia Pacific is projected to hold the largest market share during the forecast period owing to the increasing investments and advances in research and development. The pharmaceutical and biotechnology industries in the Asia Pacific region are likely to contribute significantly to the demand for structural biology and molecular modeling tools. Further, government initiatives and funding for scientific research and biotechnology can positively influence the market.
Europe is projected to have the highest CAGR over the forecast period, owing to the continuous advancements, collaborations and partnerships. Government funding, private investments and grants play a significant role in advancing research in structural biology and molecular modeling in the region. Some prominent players in the European market include Dassault Systemes, Agile Molecule and Acellera Limited. Further, funding availability and growing emphasis on personalized medicine can impact the growth of the market in europe.
Key players in the market
Some of the key players profiled in the Structural Biology & Molecular Modeling Market include Acellera Limited, Thermo Fisher Scientific Inc, Illumina Inc., Horiba, Chemical Computing Group ULC, Bruker Daltonics, Agilent Technologies Inc., Charles River Laboratories, Dassault Systemes, Biomax Informatics AG, Agile Molecule and Bioinformatic LLC.
In November 2023, The Accelra Company released a new version of ACEMD, Accela's molecular dynamics simulation software. ACEMD is a highly optimized molecular dynamics (MD) engine that runs on NVIDIA GPUs. It's free for non-profit research, but commercial licenses are available for other uses.
In September 2023, Thermo Scientific launched the new Hydra Bio Plasma-Focused Ion Beam (Plasma-FIB) for cell biologists seeking simplified workflows while undertaking volume electron microscopy for cryo or resin-embedded samples. The Hydra Bio Plasma-FIB is a versatile, multi-application instrument that supports volume electron microscopy and sample preparation for the cryo-electron tomography workflow.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.